MIMEDX GROUP, INC.

MiMedx Group, Inc. held its 2026 Annual Meeting of Shareholders on June 10, 2026, where shareholders re-elected seven directors, approved an advisory resolution on executive compensation, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, the Board of Directors approved an amendment to the company's bylaws, increasing the number of public company boards its chief executive officer may sit on to three.

MiMedx Group, Inc. announced that members of its senior management will attend the Craig-Hallum 23rd Annual Institutional Investor Conference. The event is scheduled for Thursday, May 28, 2026, in Minneapolis, MN. Investors wishing to meet with senior management are encouraged to contact their Craig-Hallum representative.

MIMEDX Group, Inc. announced the commercial launch of G4Derm Plus, an innovative 510(k)-cleared flowable biomimetic matrix for advanced wound management. The company secured exclusive U.S. distribution rights for this self-assembling peptide technology, expanding its portfolio for surgical markets. G4Derm Plus is now available through Premier and Vizient GPO agreements, facilitating a national launch and providing clinicians with a new solution for complex wounds.

MIMEDX GROUP, INC. (MDXG) will hold its 2026 Annual Meeting of Shareholders virtually on June 10, 2026, at 9:00 a.m. Eastern Time. Shareholders will vote on the election of seven directors, an advisory approval of executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026. Two current directors, M. Kathleen Behrens and Cato T. Laurencin, are not standing for re-election, reducing the board size to seven members. The Board unanimously recommends voting for all proposals.

MIMEDX GROUP, INC. announced its 2026 Annual Meeting of Shareholders will be held virtually on June 10, 2026. Shareholders of record as of April 13, 2026, are invited to vote on the election of seven directors, an advisory resolution on executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026. The Board will be reduced to seven members as two current directors are not seeking re-election.

MIMEDX Group reported a significant decline in Q1 2026, with net sales decreasing 33.1% to $59.0 million and a GAAP net loss of $(10.9) million, compared to a net income of $7.0 million in the prior year. This was primarily due to a 59.7% drop in Wound net sales following Medicare reimbursement changes, despite a 13.2% increase in Surgical net sales. The company also announced a cost reduction initiative, including a 15% workforce reduction, and launched new products while securing new distribution agreements.

MIMEDX Group, Inc. reported Q1 2026 net sales of $59 million, a 33% decrease year-over-year, primarily due to new Medicare reimbursement policies significantly impacting its Wound business, which declined 60%. The Surgical business, however, grew 13%. As a result of market disruption, the company revised its full-year 2026 net sales guidance to a range of $260 to $290 million and expects approximately breakeven Adjusted EBITDA. MIMEDX has implemented cost structure adjustments, anticipating $40 million in annualized savings, and expects a return to profitability over the balance of the year and double-digit top-line growth in 2027.

MiMedx Group, Inc. announced it will release its first quarter 2026 operating and financial results after market close on Wednesday, April 29, 2026. The company's senior management team will host a webcast and conference call to discuss the results at 4:30 p.m. Eastern Time on the same day. A replay of the webcast will be available on the company's website for approximately 30 days.

MiMedx Group, Inc. has launched a cost reduction initiative to streamline operations and significantly reduce operating expenses. As part of this, the Chief Operating Officer position was eliminated, leading to Ricci Whitlow's immediate departure. Additionally, CEO Joe Capper's base salary was cut by 20%, and other named executive officers' salaries were reduced by 10% through December 31, 2026. These actions are intended to prioritize growth opportunities and improve financial efficiency.

MiMedx Group announced a restructuring plan to reduce annual operating expenses by approximately $40 million, driven by a slow recovery in its Wound Care business following Medicare reimbursement reductions. The company will prioritize investments in its flourishing Surgical business. As part of these changes, the Chief Operating Officer position, held by Ricci Whitlow, has been eliminated, and a one-time restructuring charge of about $4 million is expected in Q2 2026.